A narrower follow-up, since the general answer is now clear:
What the dose-response curve actually looks like above 1.7mg, because the trial means hide how few people account for the extra loss?
jim_asheville said:Six weeks on from posting: I stopped reading the weekly number and started reading a four-week average, and the "stall" I opened this thread about was…
Pushing back on jim_asheville here. Pushing back on the consensus forming here. Consistency is not the same as correctness, and a board that agrees with itself quickly is usually agreeing with the first person who sounded certain.
Worth separating that from semaglutide, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.
jim_asheville said:Six weeks on from posting: I stopped reading the weekly number and started reading a four-week average, and the "stall" I opened this thread about was…
Right, and the exception is worth naming rather than left implied, because the exception is where people get into trouble.
I would rather be corrected than agreed with, if it comes to it.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference Standardsjim_asheville said:Six weeks on from posting: I stopped reading the weekly number and started reading a four-week average, and the "stall" I opened this thread about was…
Genuinely useful, thank you. I had the facts and not the framework. I will report back once I have actually tried it.
Adding the clinical framing, because it changes how the question reads. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.